Just H, Drexler H, Hasenfuss G
Medizinische Universitätsklinik, Innere Medizin III, Freiburg, Germany.
Cardiology. 1994;84 Suppl 2:99-107. doi: 10.1159/000176462.
Pharmacotherapy of heart failure is likely to be most efficacious when individually tailored to the prevailing pathophysiological derangements. Their diagnostic definition and understanding of the mechanisms involved affords the greatest opportunity for their correction and retardation of further progression of the syndrome, together with related improvements in quality of life, reduction of morbid cardiovascular events and improvement in prognosis. Four approaches may be identified, each of which allows rational therapeutic intervention. The disordered contractile geometry of the failing ventricle gives rise to increased ventricular wall tension and myocardial hypertrophy. The phenotype change largely responsible for this progression may be retarded, halted, or even reversed by a reduction of the elevated ventricular pressure and volume induced by diuresis and/or systemic vasodilatation. Knowledge of the subcellular changes responsible for electromechanical coupling and subsequent myocardial cell contraction in the various stages of heart failure is still incomplete. Pharmacotherapeutic interventions with positive inotropic agents have not been universally clinically efficacious, though the digitalis glycosides and, more recently, drugs that increase the sensitivity of the contractile proteins to calcium appear to afford further opportunity as they do not increase myocardial energy expenditure. In this regard, reduction in heart rate is a major determinant of myocardial contractile performance. Vascular stiffness and reduced vasodilator capacity are intrinsic accompaniments of congestive heart failure and exert deleterious effects on the heart by increasing preload and afterload and on the regional circulations by reducing blood flow. The mechanisms responsible include increased activity of the sympathoadrenal and renin-angiotensin-aldosterone systems, as well as reduction of endothelium-derived relaxing factor and increased stiffness of the vascular wall due to oedema.(ABSTRACT TRUNCATED AT 250 WORDS)
心力衰竭的药物治疗若能根据当前的病理生理紊乱进行个体化调整,可能最为有效。其诊断定义以及对相关机制的理解,为纠正该综合征、延缓其进一步发展提供了最大机会,同时还能改善生活质量、减少心血管疾病相关事件并改善预后。可确定四种方法,每种方法都能进行合理的治疗干预。衰竭心室的收缩几何结构紊乱会导致心室壁张力增加和心肌肥厚。通过利尿和/或全身血管扩张降低升高的心室压力和容积,在很大程度上导致这种进展的表型变化可能会减缓、停止甚至逆转。对于心力衰竭各个阶段负责机电耦合及随后心肌细胞收缩的亚细胞变化的认识仍不完整。使用正性肌力药物的药物治疗干预在临床上并非普遍有效,尽管洋地黄糖苷以及最近出现的能增加收缩蛋白对钙敏感性的药物似乎提供了更多机会,因为它们不会增加心肌能量消耗。在这方面,心率降低是心肌收缩性能的主要决定因素。血管僵硬和血管舒张能力降低是充血性心力衰竭的内在伴随症状,通过增加前负荷和后负荷对心脏产生有害影响,并通过减少血流量对局部循环产生有害影响。其机制包括交感肾上腺系统和肾素 - 血管紧张素 - 醛固酮系统的活性增加,以及内皮衍生舒张因子减少和由于水肿导致的血管壁僵硬增加。(摘要截选至250字)